We validated the prognostic accuracy of DAB2IP CpG1 methylation by pyrosequencing quantitative methylation assay in a population of ccRCC patients from multiple Chinese centers, and in an external validation patient group from University of Texas Southwestern Medical Center at Dallas by using FFPE samples. The gene discussed is DAB2IP; the disease is nonpapillary renal cell carcinoma.